For most of the modern probiotic category, one requirement has shaped nearly every aspect of product development: microorganisms must remain alive. That requirement influences manufacturing, storage, packaging, shelf life, and, ultimately, which product formats are practical. It also created a powerful consumer shorthand – more live bacteria must mean a better product.
Postbiotics challenge that assumption.
The International Scientific Association for Probiotics and Prebiotics defines a postbiotic as a preparation of inanimate microorganisms and/or their components that confers a health benefit on the host. That last part matters. Heat-killed bacteria do not automatically become postbiotics simply because they are no longer alive. The finished preparation needs evidence of benefit.
That distinction is becoming commercially important because the evidence increasingly shows that viability is not always the feature responsible for biological activity. In several strain-specific studies, inactivated preparations have retained meaningful effects after the microorganism could no longer reproduce. In some experimental models, heat treatment has actually altered or enhanced the measured activity. The conclusion is not that postbiotics are universally better than probiotics. It is that “alive” and “effective” are not always the same requirement.
For brands working in liquid nutrition, that difference may be especially consequential. A live probiotic adds a formulation obligation: enough microorganisms must remain viable through processing and storage. Once efficacy has been demonstrated for an intentionally inactivated preparation, the objective is no longer organism survival. Heat, acidity, oxygen, water, and preservation systems still matter. The formulation team is therefore no longer trying to keep a microorganism alive while also building the beverage, shot, or concentrate consumers actually want.
When Microbial Survival Is No Longer the Constraint
That shift can move product development from protecting the microorganism first to designing the consumer experience first.
The scientific case is now stronger than it was even a few years ago. A 2024 randomized trial involving 200 adults with diarrhea-predominant irritable bowel syndrome directly compared live and heat-treated versions of the same Bifidobacterium longum CECT 7347 strain. Both significantly outperformed placebo, with numerically similar, large reductions in symptom severity. The study did not formally prove equivalence between live and heat-treated versions, but it demonstrated that loss of viability did not eliminate efficacy in that preparation.
A second direct human comparison published in 2026 adds an intriguing twist. In adults with allergic rhinitis, a heat-treated preparation of the same B. longum strain significantly improved the study’s primary symptom-and-medication outcome compared with placebo, while the live arm did not differ significantly from placebo. The trial does not prove that the heat-treated preparation was superior to the live one. Still, the result is consistent with the possibility that processing can alter biological performance rather than diminish it.
The Commercial Opportunity Is Getting Wider
The commercial environment is moving at the same time. Innova Market Insights identifies gut health as one of its major global food and beverage trends for 2026; 59% of surveyed consumers said they consider gut health important for the entire body. Separate Innova data reported by Nutrition Insight indicate that launches containing postbiotic ingredients and carrying immune or mood positioning grew at a 21% compound annual rate from July 2021 through June 2026, with Asia leading innovation.
This matters because it suggests that the category is beginning to move beyond the familiar “probiotic capsule for digestion” proposition. Consumers increasingly connect gut health with immunity, mood, energy, metabolism, and broader wellness, while brands explore more differentiated delivery formats and multi-ingredient systems. The opportunity is to make microbial science available in products where maintaining live microorganisms may be inconvenient, limiting, or unnecessary.
The opportunity also extends beyond digestive health. Postbiotics are beginning to move into immune, metabolic, and beauty-from-within propositions, opening a much wider innovation space for brands already working in everyday wellness. The science is not equally mature across every territory, but the category is clearly no longer confined to digestion.
From Probiotics to Postbiotics: The Real Question
The microbiome category has accumulated terminology faster than most consumers – and many product portfolios – can comfortably absorb it. The simplest way to understand the landscape is to focus on what each category asks the product to deliver.
A probiotic is a live microorganism that, when administered in adequate amounts, provides a health benefit. Its living state is therefore fundamental to the category. A prebiotic is a substrate selectively used by host microorganisms that results in a health benefit. A postbiotic, under the ISAPP consensus definition, is a preparation of inanimate microorganisms and/or their components that provides a health benefit.
Those definitions create an important commercial distinction.
A probiotic asks: can we keep the right organism alive in sufficient quantity until the consumer takes it?
A postbiotic asks: can we preserve and consistently deliver whatever features of this inactivated preparation drive its demonstrated benefit?
The second question is not automatically easier. It is simply different. This is why “heat-killed bacterium” and “postbiotic” should not be used as interchangeable marketing language. Heat treatment describes a manufacturing step. Postbiotic describes a scientifically defined preparation with demonstrated health benefit. A manufacturer could heat-kill a bacterial strain and create a completely inactive product. Another strain could retain activity. A third could behave differently after the same general type of processing.
The strain matters. The way it is grown matters. The way it is inactivated matters. The final preparation matters. And the claimed health outcome matters.
These nuances immediately expose a weakness in simplistic “probiotics versus postbiotics” comparisons. These are not two standardized ingredients competing in a head-to-head category test. A heat-treated Bifidobacterium studied for irritable bowel symptoms says very little about an unrelated heat-treated Lactobacillus used for another purpose. The meaningful unit of evidence is the specific preparation at the studied dose for the studied outcome.
The question for an innovation team is therefore not:
Are postbiotics better than probiotics?
It is rather:
For the benefit we want to deliver, does this particular microorganism actually need to remain alive – and, if it does not, what product possibilities become available?
That framing is more useful because some biological functions still require being alive. Living organisms can metabolize substrates, produce compounds during transit, and interact dynamically with their environment. Inactivation can remove those capabilities. Postbiotics should not therefore be presented as the inevitable successor to probiotics. They are a different technological option for cases in which health-relevant activity remains after deliberate inactivation.
What survives inactivation is more intuitive than the phrase “dead bacteria” suggests. A bacterium does not become an empty shell the moment it stops reproducing. Cellular structures and other microbial components can remain capable of interacting with the host. In Akkermansia muciniphila, for example, mechanistic work identified a pasteurization-stable outer-membrane protein, Amuc_1100, that reproduced part of the organism’s metabolic and barrier-related activity in experimental models.
Heat can also change what is exposed or preserved. In the supplied Lactiplantibacillus plantarum L-137 research, heat-treated cells generated greater interleukin-12p40 activity in mouse spleen cells than the untreated material, retained this measured activity better under simulated intestinal conditions, and performed better in a mouse colitis model. Those are preclinical findings, not proof of superior human benefit, but they make the central point clearly: inactivation is a processing variable, not simply an efficacy off-switch.
That is why the manufacturing process becomes part of a postbiotic’s identity. Changing the time, temperature, or method of inactivation may change the resulting biological preparation. From a brand perspective, that makes generic claims such as “contains heat-killed probiotics” much less meaningful than access to a defined ingredient supported by a reproducible manufacturing process and relevant human evidence.
What the Evidence Actually Shows
The strongest evidence for the “alive is optional” proposition comes from trials that compare the same strain in live and inactivated form. They remove one major source of confusion: differences between strains.
The most useful evidence falls into a handful of studies, each answering a slightly different question:
B. longum CECT 7347 – IBS-D, human trial
What happened: Both live and heat-treated preparations produced large, significant improvements versus placebo after 12 weeks. Mean symptom-score reductions were 173.7 and 177.6 points, respectively, versus 60.4 with placebo.
Why it matters: This is strong evidence that viability was not required for benefit in this particular preparation. It does not prove that the live and heat-treated versions are formally equivalent.
L. paracasei LP33 – allergic rhinitis, human trial
What happened: Both live and heat-killed forms improved quality-of-life outcomes, and the researchers reported that the heat-killed preparation was not inferior to the live version.
Why it matters: It provides direct human precedent that an inactivated preparation can retain efficacy, although the study was relatively short and focused on quality of life.
B. longum CECT 7347 – allergic rhinitis, human trial
What happened: The heat-treated preparation significantly improved the primary symptom-and-medication outcome versus placebo, while the live preparation did not differ significantly from placebo.
Why it matters: Processing may change biological performance rather than reduce it. The study does not establish that the heat-treated form is superior to the live one.
Pasteurized A. muciniphila – metabolic health, human proof-of-concept
What happened: The pasteurized preparation improved insulin sensitivity and several metabolic measures compared with placebo over three months.
Why it matters: It is an important human precedent for an intentionally inactivated next-generation microorganism, although the study was exploratory and relatively small.
L. plantarum L-137 and L. paracasei HY2782 – what preclinical research adds
What happened: Heat treatment increased measured biological activity and digestive stability in L-137, while live and heat-killed HY2782 produced broadly comparable results in a mouse colitis model.
Why it matters: These studies help explain why inactivation should be treated as a processing variable rather than an automatic loss of efficacy. But they are animal or laboratory evidence, not human clinical proof.
Meaningful evidence also comes from inactivated preparations without a simultaneous live comparator. In a multicenter randomized trial involving 443 people with irritable bowel syndrome, heat-inactivated Bifidobacterium bifidum MIMBb75 produced the trial’s composite clinical response in 34% of treated participants compared with 19% receiving placebo. That study cannot tell us whether a live version would have done better, worse, or the same. Still, it demonstrates that an inactivated bacterial preparation can have clinically measurable activity in humans.
A. muciniphila is especially instructive from a commercial perspective because the story did not stop at proof-of-concept. In 2022, the European Union authorized a defined pasteurized A. muciniphila preparation as a novel food. Its specification also shows how an inactivated microbial ingredient can be characterized differently from a live probiotic: total cell count is specified, while viable cells must remain below a very low limit. That authorization relates to safety and market access as a novel food, not to approval of a specific health claim.
The evidence is now strong enough to establish the principle that some inactivated preparations retain meaningful biological activity. It is not strong enough to generalize across strains, processes, or health outcomes. As the category matures, broader replication across research groups and product settings will help strengthen confidence in how consistently these findings translate.
The value of postbiotics is not that they are probiotics without living bacteria. Their value is that, in the right preparation, meaningful microbial functionality can be separated from the requirement to keep the microorganism alive. Once those two things are separated, the category gains an entirely different degree of formulation freedom.
Formulation Freedom: Why Liquids Change the Commercial Equation
The commercial relevance of postbiotics becomes clearer at the formulation stage. For a live probiotic, being alive is part of the product specification. One common measure is the colony-forming unit (CFU) – essentially a laboratory estimate of microorganisms still capable of growing into colonies under defined test conditions. If a probiotic is supposed to deliver living organisms, viability loss during manufacturing or shelf life matters.
A validated postbiotic changes that requirement. The preparation is intentionally inanimate, so maintaining living-cell counts is no longer the objective. But removing microbial survival as a constraint does not make the ingredient indestructible. Proteins can denature, lipids can oxidize, particles can aggregate or settle, and microbial structures can interact with acids, minerals, preservatives, botanical extracts, or other components of a finished formula.
What changes is the formulation window.
Postbiotics give development teams more freedom because they no longer have to keep a microorganism alive while building the finished product. In liquids, that can matter considerably. Acidity, preservation, processing conditions, shelf life, ingredient compatibility, and sensory performance already create a demanding development environment. Removing the additional requirement of microbial survival lets more decisions focus on the needs of the whole formulation.
That does not eliminate stability work. It changes what you need to measure. Instead of asking primarily whether enough microorganisms remain viable, the development team needs to understand whether the characteristics responsible for the postbiotic’s function remain intact throughout processing and shelf life.
Emerging analytical research reflects that shift. A 2025 study on heat-killed Lacticaseibacillus paracasei NTU 101 developed a proteomics-based quality-control approach using characteristic peptides to assess identity, content, and batch consistency in a complex matrix. It is one approach rather than a universal standard, but it illustrates an important direction for the category: postbiotic quality control needs to go beyond counting living organisms.
For brands, the commercial implication is straightforward. A wider formulation window can support products ranging from daily shots and ready-to-drink beverages to concentrates and broader wellness liquids. The exact format matters less than the freedom it creates around acidity, preservation, processing, fiber dose, co-actives, serving size, and sensory experience. The selected postbiotic must remain functionally and physically suitable in the final product throughout its intended shelf life.
Consider a small wellness shot. A formulator may want a low pH for flavor and microbiological control, several grams of soluble fiber, minerals, botanical extracts, and thermal processing. With a live probiotic, each of those decisions must also be considered against microorganism survival. With an appropriately validated postbiotic, that extra survival requirement disappears. The development problem remains complex, but one constraint has been removed.
The same logic applies to ready-to-drink products, with one important caveat. An inactivated microorganism does not automatically make the finished beverage shelf-stable at ambient temperature. Shelf stability still depends on the complete formulation, processing conditions, and packaging system. The advantage is greater formulation flexibility, not automatic stability.
The Science Still Has to Taste Good
Sensory performance deserves the same attention as biological performance. Microbial biomass can contribute haze, sediment, or fermented notes. Fiber can add sweetness, body, or aftertaste. Minerals can destabilize systems. Polyphenols and proteins can introduce additional interactions. A scientifically sophisticated formulation can still fail commercially if consumers do not enjoy taking it.
That extra formulation freedom can be spent on the consumer experience – flavor, mouthfeel, serving size, convenience, and overall product identity.
Does the postbiotic still deliver what the product is built around? Processing and shelf life should not compromise the characteristics linked to its demonstrated function.
Does the finished liquid remain physically and sensorially acceptable? Sediment, separation, viscosity, flavor, aroma, and appearance need to remain within acceptable limits.
Does the product still perform as promised at the end of shelf life? That includes safety, dosing consistency, and the overall consumer experience.
Postbiotic science does not remove formulation work. It can move that work toward a more commercially useful objective: designing the best possible finished product rather than designing everything around keeping the microorganism alive.
Fiber and Broader Wellness: Building a Platform, Not a Claim Stack
Postbiotics become even more interesting when treated as part of a broader wellness platform rather than a standalone label novelty.
Fiber is an obvious partner because the two ingredient classes can play different roles.
A postbiotic supplies a defined preparation of inanimate microbial cells and/or their components. A prebiotic supplies a substrate selectively utilized by microorganisms in the host in a way that produces a health benefit. In practical terms, one can deliver microbial structures or signals directly, while the other can influence the activity of the consumer’s existing microbiota.
That is biologically complementary. It is not automatically synergistic.
“Synergy” implies more than combining two credible ingredients. Demonstrating it properly requires evidence that the combination produces an effect beyond what you’d expect from the individual components. Unless a finished combination has that evidence, postbiotic + prebiotic fiber is already a strong proposition without making the larger claim.
Fiber selection should follow the product, not the trend.
No single fiber is “best” for a postbiotic product. The right choice depends on the intended benefit, required dose, consumer tolerance, and the format being developed.
Inulin-type fructans have one of the most established prebiotic stories. Human randomized research has repeatedly shown microbiota changes, particularly increases in Bifidobacterium, at meaningful intakes. Those same fermentable properties can also create gastrointestinal symptoms for some consumers, making dose and target population important.
Partially hydrolyzed guar gum offers a different profile. In a randomized IBS study, 6 g per day improved bloating and gas-related outcomes compared with placebo, although it did not improve every measured IBS outcome. Its hydrolyzed form is substantially more practical for low-viscosity systems than intact guar, making it especially relevant to liquid concepts.
Acacia-based systems provide another route to soluble fiber delivery. Recent randomized research using a fiber mixture containing acacia gum found measurable changes in the gut microbiome. However, these did not translate into significant improvements in the study’s primary clinical outcomes.
Psyllium has strong clinical relevance for bowel function and IBS symptoms but creates a very different physical product. A randomized primary-care study found better symptom relief with psyllium than placebo during early treatment. Still, its rheology makes it a much better fit for thickened products, gels, or mix-before-use formats than for a conventional thin wellness drink.
Liquids also offer advantages over capsules. The dose of a microbial preparation may be relatively compact, while useful quantities of fiber are frequently measured in grams. A format with more physical capacity can therefore make fiber a meaningful part of the experience rather than a token label addition.
The Opportunity Extends Beyond Digestion
Postbiotics are being explored across a wider range of consumer benefit territories, but the strength of evidence varies considerably.
Digestive wellness is the most mature territory discussed in this whitepaper. The CECT 7347 and heat-inactivated MIMBb75 trials provide direct human clinical precedent for symptom-focused gastrointestinal outcomes.
Immune wellness has a plausible and increasingly commercial story, particularly because some inactivated microbial structures can continue interacting with host immune pathways. But an attractive mechanism is not the same as a permitted consumer claim. Human evidence on the selected preparation should lead the proposition, rather than relying on a cytokine result from cells or mice. The LP33 human study offers one example of clinically relevant immune-adjacent research, while L-137 shows how much mechanistic evidence can sit beneath a more cautious human proposition.
Metabolic wellness is scientifically interesting but needs even greater discipline. The pasteurized A. muciniphila proof-of-concept trial provides human evidence involving insulin sensitivity and metabolic markers, and heat-killed L-137 has human biomarker data. Neither permits brands to generalize metabolic benefits to unrelated postbiotics or to imply prevention or treatment of metabolic disease.
Beauty from within is commercially attractive because the delivery architecture already exists: shots and liquid supplements containing collagen peptides, micronutrients, ceramides, botanical extracts and polyphenols are familiar to consumers. Human trials have investigated inactivated lactobacilli for skin-related outcomes, including heat-killed Lactobacillus brevis SBC8803 and heat-killed L-137. Still, the evidence is far less mature and consistent than the strongest digestive evidence. The appropriate conclusion is not “postbiotics improve skin”; it is that skin is becoming a plausible research territory for particular preparations.
For brands, the implication is simple: start with the benefit, not the microbiome buzzword. Select a preparation with evidence relevant to that benefit, then build the formula around it with fiber and complementary actives, each serving a clear purpose. The goal is not to add more microbiome ingredients, but to build a coherent benefit system. Every important ingredient should have a reason to be there.
The Commercial Signal
The postbiotic opportunity is no longer being driven by science alone.
The commercial significance is not simply that postbiotics are appearing in more products. It is where they are appearing. The category is moving beyond a narrow digestive-health proposition and into immune, mood and broader everyday-wellness positioning – exactly the territory where format, routine and multi-ingredient formulation become strategically important.
The adjacent prebiotic market is also evolving quickly. Innova reported a 10% compound annual increase in supplement launches containing prebiotics between 2020 and 2024, with digestive, immune, and energy-related claims among the most prominent.
These signals are more useful for strategic planning than a single headline estimate of the “global postbiotics market.” Commercial market-size reports apply different definitions, category boundaries, and methodologies to a still-emerging ingredient class. Consumer behavior and launch activity tell a clearer story: gut health is expanding into broader wellness, postbiotics are appearing in that expansion, and the category is becoming more comfortable with multi-benefit propositions.
The opportunity for liquid brands sits inside that movement.
A capsule can deliver an active ingredient efficiently. A liquid creates a different kind of product opportunity: enough physical capacity for meaningful fiber doses and multiple actives, combined with a format that fits naturally into morning wellness, beauty, digestive-health, or functional-beverage routines. The postbiotic advantage is that microbial science can potentially enter those architectures without forcing every formulation decision to protect a living organism.
From Ingredient Trend to Brand Opportunity
Postbiotics are unlikely to replace probiotics, and that should not be the ambition.
Live microorganisms remain entirely logical where living metabolism or other viability-dependent functions drive efficacy. The more interesting opportunity is that brands no longer have to assume microbial health science and viable microorganisms are inseparable. For some preparations, the evidence says they are not.
That creates a new strategic space between conventional probiotic supplements and the expanding world of functional beverages, wellness shots, beauty liquids, and multi-benefit nutrition. The smartest use of that space is not to chase the word postbiotic. It is to ask what the absence of a viability requirement allows a product to become:
- A digestive-health product can combine credible microbial evidence with a meaningful fiber dose rather than forcing the entire proposition into a capsule.
- A daily wellness shot can integrate gut support into a broader routine without making the microorganism’s survival the dominant formulation constraint.
- A beauty brand can investigate microbiome science without pretending that every bacterial ingredient automatically supports skin.
- An immune or whole-body wellness brand can use the growing consumer connection between gut health and broader well-being while keeping the actual claim tied to the selected ingredient’s evidence.
- A beverage brand can bring microbiome positioning into formats that are awkward for many live cultures, while still respecting that a postbiotic’s relevant components need their own stability validation.
The most attractive first territory remains one where science, consumer understanding, and formulation opportunity overlap.
Early probiotic products often competed on numbers: billions of organisms, more strains, higher counts. Postbiotics have an opportunity to compete differently – on specific evidence, specific function, product experience, and format freedom.
For brands, this creates a particularly compelling position. The product doesn’t have to look like a probiotic supplement just because microbial science is part of the story. It can look, taste, and behave like a modern wellness product.
And that may ultimately be the more important innovation.
Sources & Footnotes
Salminen S, Collado MC, Endo A, et al. The International Scientific Association for Probiotics and Prebiotics (ISAPP) consensus statement on the definition and scope of postbiotics. Nature Reviews Gastroenterology & Hepatology. 2021;18:649–667. doi:10.1038/s41575-021-00440-6
Srivastava S, Basak U, Naghibi M, et al. A randomized double-blind, placebo-controlled trial to evaluate the safety and efficacy of live Bifidobacterium longum CECT 7347 and heat-treated Bifidobacterium longum CECT 7347 in participants with diarrhea-predominant irritable bowel syndrome. Gut Microbes. 2024;16:2338322. doi:10.1080/19490976.2024.2338322
Fujiki T, Hirose Y, Yamamoto Y, Murosaki S. Enhanced immunomodulatory activity and stability in simulated digestive juices of Lactobacillus plantarum L-137 by heat treatment. Bioscience, Biotechnology, and Biochemistry. 2012;76:918–922. doi:10.1271/bbb.110919
Cardoso A, Naghibi M, Climent E, et al. Effects of live and heat-treated Bifidobacterium longum CECT 7347 in adults with allergic rhinitis: a randomised, double-blind, placebo-controlled trial. Allergy. 2026. doi:10.1111/all.70360
Innova Market Insights. Innova’s Top Ten Trends 2026: shaping the future of food & beverage. 2026. Source
Nutrition Insight / Innova Market Insights. Postbiotics for immunity and mood. Nutrition Focus. 2026. Source
Depommier C, Everard A, Druart C, et al. Supplementation with Akkermansia muciniphila in overweight and obese human volunteers: a proof-of-concept exploratory study. Nature Medicine. 2019;25:1096–1103. doi:10.1038/s41591-019-0495-2
Ogawa M, Saiki A, Matsui Y, et al. Effects of oral intake of heat-killed Lactobacillus brevis SBC8803 (SBL88™) on dry skin conditions: a randomized, double-blind, placebo-controlled study. Experimental and Therapeutic Medicine. 2016;12:3863–3872. doi:10.3892/etm.2016.3862
Yoshitake R, Nakai H, Ebina M, et al. Beneficial effect of heat-killed Lactiplantibacillus plantarum L-137 on skin functions in healthy participants: a randomized, placebo-controlled, double-blind study. Frontiers in Medicine. 2022;9:912280. doi:10.3389/fmed.2022.912280
Gibson GR, Hutkins R, Sanders ME, et al. Expert consensus document: The International Scientific Association for Probiotics and Prebiotics consensus statement on the definition and scope of prebiotics. Nature Reviews Gastroenterology & Hepatology. 2017;14:491–502. doi:10.1038/nrgastro.2017.75
Plovier H, Everard A, Druart C, et al. A purified membrane protein from Akkermansia muciniphila or the pasteurized bacterium improves metabolism in obese and diabetic mice. Nature Medicine. 2017;23:107–113. doi:10.1038/nm.4236
Peng GC, Hsu CH. The efficacy and safety of heat-killed Lactobacillus paracasei for treatment of perennial allergic rhinitis induced by house-dust mite. Pediatric Allergy and Immunology. 2005;16:433–438. doi:10.1111/j.1399-3038.2005.00284.x
Lee D, Gwon H, Jeong JW, et al. Preventive effects of probiotic and postbiotic Lacticaseibacillus paracasei HY2782 on DSS-induced colitis in mice: comparable efficacy of live and heat-killed forms. Journal of Microbiology and Biotechnology. 2026;36:e2512027. doi:10.4014/jmb.2512.12027
Andresen V, Gschossmann J, Layer P. Heat-inactivated Bifidobacterium bifidum MIMBb75 (SYN-HI-001) in the treatment of irritable bowel syndrome: a multicentre, randomised, double-blind, placebo-controlled clinical trial. The Lancet Gastroenterology & Hepatology. 2020;5:658–666. doi:10.1016/S2468-1253(20)30056-X
European Commission. Commission Implementing Regulation (EU) 2022/168 authorising the placing on the market of pasteurised Akkermansia muciniphila as a novel food. 2022. Source
Wu CW, Shih TW, Pan TM. Development of a quality control method for postbiotics based on stable isotope dimethyl labeling and liquid chromatography-tandem mass spectrometry of heat-killed Lacticaseibacillus paracasei subsp. paracasei NTU 101. LWT. 2025;231:118368. doi:10.1016/j.lwt.2025.118368
Vandeputte D, Falony G, Vieira-Silva S, et al. Prebiotic inulin-type fructans induce specific changes in the human gut microbiota. Gut. 2017;66:1968–1974. doi:10.1136/gutjnl-2016-313271
Reimer RA, Soto-Vaca A, Nicolucci AC, et al. Effect of chicory inulin-type fructan-containing snack bars on the human gut microbiota in low dietary fiber consumers in a randomized crossover trial. The American Journal of Clinical Nutrition. 2020;111:1286–1296. doi:10.1093/ajcn/nqaa074
Bruhwyler J, Carreer F, Demanet E, Jacobs H. Digestive tolerance of inulin-type fructans: a double-blind, placebo-controlled, crossover, dose-ranging, randomized study in healthy volunteers. International Journal of Food Sciences and Nutrition. 2009;60:165–175. doi:10.1080/09637480701625697
Niv E, Halak A, Tiommny E, et al. Randomized clinical study: partially hydrolyzed guar gum (PHGG) versus placebo in the treatment of patients with irritable bowel syndrome. Nutrition & Metabolism. 2016;13:10. https://pmc.ncbi.nlm.nih.gov/articles/PMC4744437/
Eveleens Maarse BC, Eggink HM, Warnke I, et al. Impact of fibre supplementation on microbiome and resilience in healthy participants: a randomized, placebo-controlled clinical trial. Nutrition, Metabolism and Cardiovascular Diseases. 2024;34:1416–1426. doi:10.1016/j.numecd.2024.01.028
Bijkerk CJ, de Wit NJ, Muris JWM, et al. Soluble or insoluble fibre in irritable bowel syndrome in primary care? Randomised placebo controlled trial. BMJ. 2009;339:b3154. doi:10.1136/bmj.b3154
Tanaka Y, Hirose Y, Yamamoto Y, Yoshikai Y, Murosaki S. Daily intake of heat-killed Lactobacillus plantarum L-137 improves inflammation and lipid metabolism in overweight healthy adults: a randomized-controlled trial. European Journal of Nutrition. 2020;59:2641–2649. doi:10.1007/s00394-019-02112-3
Nutrition Insight / Innova Market Insights. Prebiotic proliferation. 1 May 2025. Source